Clinical trial
Simple Blind, Placebo Controlled, Randomized, Two-stage, Prospective, Single-center Safety, Tolerability and Reactogenicity Trial of the [Recombinant Tuberculosis Allergen in Standard Dilution], Solution for Intradermal Injection, 0.1 mL/Dose, Produced by FSUE SPbSRIVS FMBA of Russia, in Healthy Volunteers After a Single Dose in the Dilution of 0.1 µg / 0.1 mL or 0.2 µg / 0.1 mL
NCT05398562 is registered in ClinicalTrials.gov with St. Petersburg Research Institute of Vaccines and Sera as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Simple Blind, Placebo Controlled, Randomized, Two-stage, Prospective, Single-center Safety, Tolerability and Reactogenicity Trial of the [Recombinant Tuberculosis Allergen in Standard Dilution], Solution for Intradermal Injection, 0.1 mL/Dose, Produced by FSUE SPbSRIVS FMBA of Russia, in Healthy Volunteers After a Single Dose in the Dilution of 0.1 µg / 0.1 mL or 0.2 µg / 0.1 mL
- Lead sponsor
- St. Petersburg Research Institute of Vaccines and Sera
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- February 13, 2020
- Completion date
- June 26, 2020
- Enrollment
- 75 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
skin tests, tuberculosis